Arbutus Biopharma Corporation (ABUS) Q3 2022 Earnings Call Transcript

Nov. 09, 2022 10:42 AM ETArbutus Biopharma Corporation (ABUS)
SA Transcripts profile picture
SA Transcripts
133.94K Followers

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2022 Earnings Conference Call January 1, 2022 8:45 AM ET

Company Participants

Lisa Caperelli - Vice President of Investor Relations

Bill Collier - President and Chief Executive Officer

David Hastings - Chief Financial Officer

Gaston Picchio - Chief Development Officer

Mike Sofia - Chief Scientific Officer

Conference Call Participants

Dennis Ding - Jefferies

Roy Buchanan - JMP

Keay Nakae - Chardan

Operator

Good day. And thank you for standing by, and welcome to Arbutus Biopharma Corporation's 2022 Third Quarter Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Lisa Caperelli, Vice President of Investor Relations. You may begin.

Lisa Caperelli

Thanks, Justin. Good morning, everyone, and thank you for joining Arbutus' third quarter 2022 financial results and corporate update call. Joining me today from the Arbutus executive team are Bill Collier, President and Chief Executive Officer; David Hastings, Chief Financial Officer; Dr. Gaston Picchio, Chief Development Officer; and Dr. Mike Sofia, Chief Scientific Officer.

Bill will begin with a corporate update, followed by Dave, who will provide a review of the company's third quarter 2022 financial results. After opening remarks, we will open the call for Q&A. Gaston and Mike will be available to address clinical development and research-related questions.

Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements, which are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in our most recent annual report on 10-K, quarterly report on Form 10-Q to

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.